ArticleTranslational vision science & technology2026
Anti-IL-6 Receptor Antibody Suppresses Visual Dysfunction in AQP4 Peptide-Immunized Mice.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate whether an anti-interleukin-6 (IL-6) receptor antibody (MR16-1) can prevent retinal and optic nerve dysfunction, as well as myelitis, in a mouse model of myelitis induced by immunization with aquaporin-4 (AQP4) peptide. Methods: Mice immunized with AQP4 peptide received MR16-1 or vehicle. Retinal function was assessed by electroretinography (ERG), including b-wave, a-wave, and positive scotopic threshold response (pSTR) amplitudes. Histologic analysis evaluated inflammatory cell infiltration and aberrant Müller cell activation (punctate pattern of glial fibrillary acidic protein staining). Blood-retinal barrier (BRB) integrity was assessed using Evans blue dye, IgG leakage, and transendothelial electrical resistance (TEER) in primary mouse retinal microvascular endothelial cells (mRMECs) exposed to mouse serum. Results: AQP4 peptide immunization led to reductions in ERG b-wave and pSTR amplitudes and increased inflammatory cell infiltration, Müller cell alteration, and retinal vascular permeability. MR16-1 treatment significantly mitigated these changes, suppressing reductions in pSTR and b-wave amplitude, preventing inflammation and aberrant Müller cell activation, and reducing vascular leakage. The improvement of a-wave amplitude was not significant. Serum from MR16-1-treated mice did not reduce mRMEC TEER, while serum from AQP4 peptide-immunized mice reduced it. Conclusions: IL-6 receptor blockade with MR16-1 has the potential to suppress AQP4 peptide immunization-related retinal and optic nerve dysfunction and pathology, likely by protecting BRB integrity and suppressing inflammation. These findings support the therapeutic potential of IL-6 inhibition in preserving visual function in neuromyelitis optica spectrum disorder (NMOSD). Translational Relevance: IL-6 receptor blockade may be a viable strategy for preventing visual impairment in patients with NMOSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.